Central nervous system adverse effects with efavirenz: Case report and review

Pharmacotherapy

Volumn 22, Issue 7, 2002, Pages 930-933

  Puzantian, Talia ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; OXAZINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DELUSION; DEPRESSION; DRUG MONITORING; HALLUCINATION; HEADACHE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALE; MENTAL HOSPITAL; PARANOIA; SUICIDE ATTEMPT; VERTIGO; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; REVIEW;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OXAZINES;

EID: 0035990396     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.11.930.33624     Document Type: Article

References (8)

1. Potential adverse experiences associated with efavirenz (Sustiva) in adults
2. Tricks of the trade in starting efavirenz therapy
3. Psychiatric illness and efavirenz study (PIES)
4. Efavirenz use in HIV infected patients with a psychiatric history
5. Efavirenz (EFV) tolerability in the real world: Relation to mental illness, alcohol, and illicit drug use in a large, urban HIV clinic
6. Management of sudden psychiatric disorders related to efavirenz
7. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients